Combined Measles, Mumps, Rubella and Varicella Vaccine for Children
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administration of the MMRV (Merck's measles, mumps, rubella and varicella) vaccine (ProQuad) that is already licensed for this route, when administered as a second dose in children 15 months to 6 years of age who were previously primed with a first dose of any combination of measles, mumps, rubella and varicella-containing vaccine(s).
Are You a Good Fit for This Trial?
This trial is for healthy children aged 15 months to 6 years who have already received their first dose of measles, mumps, rubella, and chickenpox (varicella) vaccines. Parents or guardians must give consent, and the child should be able to follow study procedures.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- MMRV
- MMRVNS
Trial Overview
The study compares a new combined vaccine (MMRVNS) with an approved vaccine (MMRV/ProQuad), both given as a second shot by muscle injection. The goal is to see how well each works and how safe they are in young children.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Children, 15 months to 6 years old, who will receive one dose of MMRVNS on Day 1.
Children, 15 months to 6 years old, who will receive one dose of MMRV on Day 1.
Find a Clinic Near You
Who Is Running the Clinical Trial?
GlaxoSmithKline
Lead Sponsor
Dame Emma Walmsley
GlaxoSmithKline
Chief Executive Officer since 2017
MA in Classics and Modern Languages from Oxford University
Dr. Hal Barron
GlaxoSmithKline
Chief Medical Officer since 2018
MD from Harvard Medical School
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.